Bristol-Myers Squibb [clinicaltrials_resource:3198a154b3c6ab71c470cee213664836]
clinicaltrials:NCT01087125clinicaltrials:NCT01204775Study to Evaluate the Safety and Tolerability of IV Doses of BMS-906024 in Subjects With Advanced or Metastatic Solid Tumors [clinicaltrials:NCT01292655]clinicaltrials:NCT01363817clinicaltrials:NCT01434186clinicaltrials:NCT01450761clinicaltrials:NCT01454102clinicaltrials:NCT01471210Safety Study in Nivolumab Alone and in Combination With Ipilimumab or Lirilumab in Lymphoma and Multiple Myeloma [clinicaltrials:NCT01592370]clinicaltrials:NCT01593254clinicaltrials:NCT01614756clinicaltrials:NCT01621490clinicaltrials:NCT01653470clinicaltrials:NCT01658878clinicaltrials:NCT01696045clinicaltrials:NCT01707394A Phase I Study of an Anti-KIR Antibody in Combination With an Anti-PD1 Antibody in Patients With Advanced Solid Tumors [clinicaltrials:NCT01714739]clinicaltrials:NCT01714817clinicaltrials:NCT01758198Safety and Efficacy of a Lysophosphatidic Acid Receptor Antagonist in Idiopathic Pulmonary Fibrosis [clinicaltrials:NCT01766817]clinicaltrials:NCT01775631Phase II Pharmacokinetics, Efficacy, and Safety of Belatacept in Pediatric Renal Transplant Recipients [clinicaltrials:NCT01791491]A Study in Maintenance Kidney Transplant Recipients Following Conversion to Nulojix® (Belatacept)-Based [clinicaltrials:NCT01820572]clinicaltrials:NCT01835470clinicaltrials:NCT01844518clinicaltrials:NCT01850004clinicaltrials:NCT01864174clinicaltrials:NCT01884350Eliquis Regulatory Post Marketing Surveillance (rPMS) [clinicaltrials:NCT01885585]Eliquis Regulatory Post Marketing Surveillance [clinicaltrials:NCT01885598]A Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab in Subjects With Advanced or Metastatic Solid Tumors [clinicaltrials:NCT01928394]Forxiga Prescription Event Monitoring Program [clinicaltrials:NCT01944618]clinicaltrials:NCT01968109Phase I Ascending Multiple-Dose Study of BMS-986115 in Subjects With Advanced Solid Tumors [clinicaltrials:NCT01986218]Eliquis Safety Surveillance in Japanese Patients With NonValvular Atrial Fibrillation [clinicaltrials:NCT02007655]clinicaltrials:NCT02011945clinicaltrials:NCT02017717clinicaltrials:NCT02038933clinicaltrials:NCT02038946clinicaltrials:NCT02041533
overall contact [clinicaltrials_vocabulary:overall-contact]
Bristol-Myers Squibb [clinicaltrials_resource:3198a154b3c6ab71c470cee213664836]
Bio2RDF identifier
3198a154b3c6ab71c470cee213664836
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:3198a154b3c6ab71c470cee213664836
affiliation [clinicaltrials_vocabulary:affiliation]
email [clinicaltrials_vocabulary:email]
Clinical.Trials@bms.com
last name [clinicaltrials_vocabulary:last-name]
Bristol Myers Squibb
Bristol-Myers Squibb
Recruiting sites have contact ...... act information, please email:
phone [clinicaltrials_vocabulary:phone]
+49401818863216
203-737-1889
205-638-2792
205-934-7220
205-934-7630
205-949-1907
205-975-8091
205-996-9191
205-996-9569
251-607-5283
phone ext [clinicaltrials_vocabulary:phone-ext]
role [clinicaltrials_vocabulary:role]
Study Director
identifier
clinicaltrials_resource:3198a154b3c6ab71c470cee213664836
title
Bristol-Myers Squibb
@en
type
label
Bristol-Myers Squibb [clinicaltrials_resource:3198a154b3c6ab71c470cee213664836]
@en